Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 4;320(9):931-933.
doi: 10.1001/jama.2018.7316.

Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

Jinoos Yazdany  1 , R Adams Dudley  2 , Grace A Lin  2 , Randi Chen  3 , Chien-Wen Tseng  4
Affiliations

Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

Jinoos Yazdany et al. JAMA. .

Abstract

This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Yazdany has received an independent investigator award from Pfizer. No other disclosures were reported.

Figures

Figure.
Figure.. Standard Cost-Sharing Structure of Medicare Part D Drug Benefits in 2017
Adapted with permission from Kaiser Family Foundation Medicare Part D Prescription Drug Benefit. aIn our analyses, patients’ out-of-pocket costs were based on average cost-sharing requirements for each drug across all Part D plans nationwide. bManufacturer discount counts as out-of-pocket cost to reach catastrophic coverage threshold.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. https://www.rand.org/pubs/perspectives/PE264.html. Accessed April 9, 2018. - PMC - PubMed
    1. Centers for Medicare & Medicaid Services 2015 Medicare drug spending dashboard. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Tren.... Accessed April 9, 2018.
    1. Yazdany J, Dudley RA, Chen R, Lin GA, Tseng CW. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis Rheumatol. 2015;67(6):1474-1480. doi:10.1002/art.39079 - DOI - PMC - PubMed
    1. Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017;317(21):2163-2164. doi:10.1001/jama.2017.5202 - DOI - PubMed
    1. Kaiser Family Foundation The Medicare Part D prescription drug benefit. https://www.kff.org/medicare/fact-sheet/the-medicare-prescription-drug-b.... Accessed April 9, 2018.

Publication types